Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.48 |
| ▸ | ACACA | Q13085 | 14/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493044 | 1.00 | ACACB (0.48) | ACACBACACATSHRCYP1A2ALDH1A1 | |
| SCHEMBL3493774 | 0.92 | ACACB (0.49) | ACACBACACA | |
| SCHEMBL3493771 | 0.92 | ACACB (0.49) | ACACBACACA | |
| SCHEMBL3493094 | 0.90 | ACACB (0.39) | ACACBACACATSHRCYP1A2CYP3A4 | |
| SCHEMBL3493096 | 0.90 | ACACB (0.39) | ACACBACACATSHRCYP1A2CYP3A4 | |
| SCHEMBL3491551 | 0.89 | ACACB (0.40) | ACACBACACATSHRCYP1A2ALDH1A1 | |
| SCHEMBL3491550 | 0.89 | ACACB (0.40) | ACACBACACATSHRCYP1A2ALDH1A1 | |
| SCHEMBL3494529 | 0.87 | ACACB (0.52) | ACACBACACA | |
| SCHEMBL3494526 | 0.87 | ACACB (0.52) | ACACBACACA | |
| SCHEMBL3494572 | 0.86 | SMN1; SMN2 (0.33) | ACACBACACAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | ACACB 5/4885ACACA 1/4885TSHR 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.